CHC promotes tumor growth and angiogenesis through regulation of HIF-1α and VEGF signaling

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 58-67

  Tung, Kuo Hua ^a,b   Lin, Cheng Wei ^a   Kuo, Chun Chen ^a   Li, Li Tzu ^a   Kuo, Ya Hsun ^a   Lin, Chung Wu ^b   Wu, Han Chung ^a,b  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Clathrin heavy chain; HIF 1 ; Monoclonal antibody; Pancreatic cancer

Indexed keywords

CLATHRIN HEAVY CHAIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PA65 2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873522077     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.001     Document Type: Article

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 2012, 62:10-29.
2. Ischenko I., Seeliger H., Jauch K.W., Bruns C.J. Metastatic activity and chemotherapy resistance in human pancreatic cancer-influence of cancer stem cells. Surgery 2009, 146:430-434.
3. Mini E., Nobili S., Caciagli B., Landini I., Mazzei T. Cellular pharmacology of gemcitabine. Ann. Oncol. 2006, 17(Suppl. 5):v7-12.
4. Cascinu S., Berardi R., Labianca R., Siena S., Falcone A., Aitini E., Barni S., Di Costanzo F., Dapretto E., Tonini G., Pierantoni C., Artale S., Rota S., Floriani I., Scartozzi M., Zaniboni A. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008, 9:39-44.
5. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., Verslype C., Scheithauer W., Shang A., Cosaert J., Moore M.J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:2231-2237.
6. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., Picus J., Bhargava P., Mayer R.J., Schilsky R.L., Goldberg R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010, 28:3617-3622.
7. Starling N., Watkins D., Cunningham D., Thomas J., Webb J., Brown G., Thomas K., Oates J., Chau I. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J. Clin. Oncol. 2009, 27:5499-5505.
8. Kirchhausen T. Clathrin. Annu. Rev. Biochem. 2000, 69:699-727.
9. Schmid S.L. Clathrin-mediated endocytosis: a universe of new questions. Mol. Biol. Cell 2010, 21:3818-3819.
10. Royle S.J., Bright N.A., Lagnado L. Clathrin is required for the function of the mitotic spindle. Nature 2005, 434:1152-1157.
11. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
12. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
13. Cabuk D., Basaran G., Celikel C., Dane F., Yumuk P.F., Iyikesici M.S., Ekenel M., Turhal N.S. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 2007, 72:111-117.
14. Lundgren K., Holm C., Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell. Mol. Life Sci. 2007, 64:3233-3247.
15. Hung J.J., Yang M.H., Hsu H.S., Hsu W.H., Liu J.S., Wu K.J. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009, 64:1082-1089.
16. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2003, 2:803-811.
17. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 2009, 13:2780-2786.
18. Lee T.Y., Wu H.C., Tseng Y.L., Lin C.T. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 2004, 64:8002-8008.
19. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
20. Wu H.C., Jung M.Y., Chiu C.Y., Chao T.T., Lai S.C., Jan J.T., Shaio M.F. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J. Gen. Virol. 2003, 84:2771-2779.
21. Liu I.J., Chiu C.Y., Chen Y.C., Wu H.C. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J. Biol. Chem. 2011, 286:9726-9736.
22. Lu T.Y., Kao C.F., Lin C.T., Huang D.Y., Chiu C.Y., Huang Y.S., Wu H.C. DNA methylation and histone modification regulate silencing of OPG during tumor progression. J. Cell. Biochem. 2009, 108:315-325.
23. Lin C.W., Liao M.Y., Lin W.W., Wang Y.P., Lu T.Y., Wu H.C. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming Factors and Epithelial-Mesenchymal transition gene expression in colon cancer. J. Biol. Chem. 2012, 287:39449-39459.
24. Wu S.R., Cheng T.S., Chen W.C., Shyu H.Y., Ko C.J., Huang H.P., Teng C.H., Lin C.H., Johnson M.D., Lin C.Y., Lee M.S. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am. J. Pathol. 2010, 177:3145-3158.
25. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
26. Lu T.Y., Lu R.M., Liao M.Y., Yu J., Chung C.H., Kao C.F., Wu H.C. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J. Biol. Chem. 2010, 285:8719-8732.
27. Bonazzi M., Spano S., Turacchio G., Cericola C., Valente C., Colanzi A., Kweon H.S., Hsu V.W., Polishchuck E.V., Polishchuck R.S., Sallese M., Pulvirenti T., Corda D., Luini A. CtBP3/BARS drives membrane fission in dynamin-independent transport pathways. Nat. Cell Biol. 2005, 7:570-580.
28. Chang D.K., Chiu C.Y., Kuo S.Y., Lin W.C., Lo A., Wang Y.P., Li P.C., Wu H.C. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 2009, 284:12905-12916.
29. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 2011, 12:517-533.
30. Goh L.K., Huang F., Kim W., Gygi S., Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 2010, 189:871-883.
31. Di Tommaso L., Destro A., Fabbris V., Spagnuolo G., Laura Fracanzani A., Fargion S., Maggioni M., Patriarca C., Maria Macchi R., Quagliuolo M., Borzio M., Iavarone M., Sangiovanni A., Colombo M., Roncalli M. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011, 53:1549-1557.
32. Seimiya M., Tomonaga T., Matsushita K., Sunaga M., Oh-Ishi M., Kodera Y., Maeda T., Takano S., Togawa A., Yoshitomi H., Otsuka M., Yamamoto M., Nakano M., Miyazaki M., Nomura F. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 2008, 48:519-530.
33. Palamidessi A., Frittoli E., Garre M., Faretta M., Mione M., Testa I., Diaspro A., Lanzetti L., Scita G., Di Fiore P.P. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 2008, 134:135-147.
34. Scita G., Di Fiore P.P. The endocytic matrix. Nature 2010, 463:464-473.
35. Joffre C., Barrow R., Menard L., Calleja V., Hart I.R., Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat. Cell. Biol. 2011, 13:827-837.
36. Lampugnani M.G., Orsenigo F., Gagliani M.C., Tacchetti C., Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 2006, 174:593-604.
37. Moskowitz H.S., Yokoyama C.T., Ryan T.A. Highly cooperative control of endocytosis by clathrin. Mol. Biol. Cell 2005, 16:1769-1776.
38. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
39. Schmid S.L. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 1997, 66:511-548.
40. Marks B., Stowell M.H., Vallis Y., Mills I.G., Gibson A., Hopkins C.R., McMahon H.T. GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature 2001, 410:231-235.
41. Enari M., Ohmori K., Kitabayashi I., Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev. 2006, 20:1087-1099.
42. Kim M.L., Sorg I., Arrieumerlou C. Endocytosis-independent function of clathrin heavy chain in the control of basal NF-kappaB activation. PLoS One 2011, 6:e17158.
43. Kong X., Lin Z., Liang D., Fath D., Sang N., Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 2006, 26:2019-2028.
44. Zhang D., Li J., Costa M., Gao J., Huang C. JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res. 2010, 70:813-823.
45. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002, 277:29936-29944.
46. Sorkin A., Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat. Rev. Mol. Cell Biol. 2002, 3:600-614.
47. Ohata H., Ota N., Shirouzu M., Yokoyama S., Yokota J., Taya Y., Enari M. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation. J. Mol. Biol. 2009, 394:460-471.